CyDex presents strong data for nasal sprays

Kansas, USA-based CyDex Pharmaceuticals presented Phase II trial results for its Captisol-Enabled budesonide/azelastine nasal spray for seasonal  allergic rhinitis, demonstrating statistically-significant improvements  over placebo, at the American Academy of Allergy, Asthma & Immunology  annual meeting in Washington DC.

A randomized, double-blind, placebo-controlled, three-way cross-over  study was conducted in 108 SAR patients to compare the relative efficacy  of Captisol-Enabled Budesonide plus Azelastine Nasal Spray (Single  Solution) and Rhinocort Aqua (Suspension) plus Astelin Nasal Spray  (Solution) against a placebo nasal spray solution in the treatment of  allergic rhinitis in an environmental exposure chamber.

Relief of all nasal symptoms was significantly greater than placebo from  20 minutes to 10 hours following administration for both Captisol and  Rhinocort (p<0.0001). Onset of action of relief from itchy nose and  sneezing were significantly faster at 10 minutes for Captisol compared  to Rhinocort. Relief of all eye symptoms was significant from 40  minutes.